|
(1) Huang A. C., Lin T. P., Kuo S. C., and Wang J. P., The antiallergic activities of synthetic acrophylline and acrophyllidine. Journal of natural products,1995,58, 117-120
(2) Chang G.J., Su M.J., Kuo S.C., Lin T.P. and Lee Y.S., Multiple cellular electrophysiological effects of a novel antiarrhythmic furoquinoline derivative HA-7 [N-benzyl-7-methoxy-2,3,4,9- tetrahydro furo[2,3-b]quinoline-3,4-dione] in guinea pig cardiac preparations. J Pharmacol Exp Ther, 2006, 316:380-391.
(3) Lin T. P., Huang A. C., Wei H. C., Lin J. G. and Chung J. G., Ethyl
2-[N-p-chlorobenzyl-(2`-methyl)]anilino-4-oxo-4,5-dihydrofuran-3-
carboxylate(JOT01007)Induces Apoptosis in Human Cervical Cancer Ca Ski Cells. In vivo,2007,21:397-406
(4) Chen Y. L., Chen I. L., Wang T. C., Han C. H. and Tzeng C. C., Synthesis and anticancer evaluation of certain 4-anilinofuro [2,3-b] quinoline and 4-anilinofuro[3,2-c]quinoline derivatives. European Journal of Medicinal Chemistry ,2005 ,40 ,928–934
(5) Huang A. C., Chung J. G, Kuo S.C., Lu H.F. and Lin T. P, Synthesis and cytotoxic activity of certain 2,3,4,9-tetrahydrofuro [2,3-b]quinolin -3,4-dione and Ethyl 2-(substituted aniline)-4-oxo-Dihydrofuran-3- carboxylate derivatives in Murine Leukemia WEHI-3 cells. In vivo 2007,21:227-236
(6) Lahey F. N. and McCamish M., Acrophylline and Acrophyllidine. Two new alkaloids from Acronychia haplophylla. Tetrahedron Letters, 1968, 12, 1525-1527 .
(7) Nam K.W., Je K.H., Shin Y.J., Kang S.S. and Mar W., Inhibitory effects of furoquinoline alkaloids from Melicope confusa and Dictamnus albus against human phosphodiesterase 5 (hPDE5A)
in vitro. Arch Pharm Res, 2005, 28:675-679.
(8) Woo W. S., Lee E. B., Kang S. S., Shin K. H. and Chi H. J., Antifertility principle of Dictamnus albus root bark. Planta Medica, 1987, 53 (5), 399- 401 .
(9) Mooken, J. D.; Bailey, V. L.; Bailey, H. E., Occurrence of furo- quinoline alkaloids in Ptelea trifoliata. Lloydia, 1969, 32 , 526-7.
(10) Sakar M., Kundu S. and Chakraborty D.P., Glycarpine, a new alkaloid from Glycosmis cyanocarpa. Phytochemistry, 1978, 17, 2145-2146.
(11) Mohr N., Budzikiewicz H., EI-Tawil B. A. H. and EI-Beih F. K. A., Further furoquinolone alkaloids from Ruta chalepensis. Phytochemistry, 1982 ,21 (7), 1838-1839 .
(12) Leonardo K., Basco, Sofia Mitaku, Alexios-Leandros Skaltsounis, etc. In Vitro Activities of Furoquinoline and Acridone Alkaloids against Plasmodium falciparum. Antimicrobial agent and chemotherapy. 1994, May , p.1169-1171.
(13) Olila. D., Olwa-Odyek and Opuda-Asibo J. Antibacterial and antifungal activities of extracts of Zanthoxylum chalybeum and Warburgia ugandensis, Ugandan medicinal plants. African Health Sciences, 2001, 1(2) ,p.66-72
(14) Cheng J. T., Chang T. K., and Cheng I. S., Skimmianine and related
furoquinolines function as antagonists of 5-hydroxytryptamine receptors in
animals. J. Auto. Pharmacol., 1994, 14, 365- 374.
(15) Mitscher LA ., Antimicrobial agents from higher plants . The anti- microbially inactive components of Ptelea trifoliata L., Lloydia, 1975, 38(2), 117-24.
(16) http://www.cnfda.com/read_xx_gy.asp?id=13103
(17) http://eng.ege.edu.tr/~otles/WorldOfNutraceuticals/sayfalar/page06.
htm
(18) Pfyffer G.E., Towers GH., Photochemical interaction of dictamnine, a furoquinoline alkaloid,with fungal DNA. Can J Microbiol. 1982, May; 28(5):468-73.
(19) Mitscher L. A.,T. Suzuki and Clark G., Total synthesis of 2,4- dioxyquinoline alkaloids, Heterocycles, 1976, 5, 565-604 .
(20) Zhao W., Wolfender J. L., Hostettmann K., Xu R. and Qin G., Antifungal
alkaloids and limonoid derivatives from Dictamnus dasycarpus.
Phytochemistry, 1998,47 (1), 7-11 .
(21) Yu S. M. , Ko F. N., Su M. J., Wu T. S., Wang M. L., Huang T. F. and Teng C.M., Vasorelaxing effect in rat thoracic aorta caused by fraxinellone and dictamnine isolated from the Chinese herb Dictamnus daycarpus Turcz： comparison with cromakalim and Ca+2 channel blockers. Naunyn-Sch- miedeberg''s Arch. Pharmacol., 1992, 345, 349-355 .
(22) Chen I.S., Lin Y.C., Tsai I.L., Teng C.M., Ko F.N., Ishikawa T. and
Ishii H., Coumarins and anti-platelet aggregation constituents from
Zanthoxylum schinifolium. Phytochemistry , 1995, 39:1091-1097.
(23) Chen K. S., Chang Y. L., Teng C. M., Chen and C. F., Wu Y. C., Furo- quinolines with antiplatelet aggregationactivity from leaves of Melicope confusa. Planta Medica, 2000,66, 80-81.
(24) Chang G. J., Wu M. H., Chen W. P., Kuo S. C. and Su M. J., Electrophysi- ological characteristics of antiarrhythymic potential of acrophyllidine, a filroquinoline alkaloid isolated from Acronychia halophylla. Drug development research, 2000 , 50, 170-185 .
(25) Govindachari T. R., Prabhakal S., Ramachandran V. N., and Pal B. R., Synthetic of Medicosmine. Indian J. Chem. ,1971, 9, 1031-1041 .
(26) Narasimhan N. S., Paradkar M. V. and Alurkar R. H., Synthetic application
of lithiation reactions-IV novel synthesis of linear furoquinoline alkaloids
and a synthesis of edulitine. Tetrahedron, 1971, 27, 1351-1356 .
(27) Narasimhan N. S. and Mall R. S., Synthetic application of lithiation reactions -VI new synthesis of linear fhroquinoline alkaloids. Tetrahedron, 1974 , 30, 4153 - 4157
(28) Narasimhan N. S. and Alurkar R. H., Synthesis of dihydro-γ-fagarine and edulitine, Chem. Ind., 1968, 515
(29) Narasimhan N. S. and Paradkar M. V., A new synthesis of the furo[2,3-b] quinolines：a synthesis of dictamnine. Chem. Ind., 1967,831-832 .
(30) Huffman J. W., Garg S. P. and Cecil J. H., The furanoquinoline alkaloids III. An attempted synthesis of dl-lunacrine and correction of the structure of demethoxylunacrine. J. Org. Chem., 1966, 31, 1276-1279 .
(31) Huffman J. W. and Cecil J. H., Reaction of some acylquinolones with diazomethane,. J. Org. Chem., 1969 , 34, 2183-2187 .
(32) Bowman R. M. and Grundon M. F., Quinoline alkaloids IX. A partial asymmetric synthesis of orixine. J. Chem. Soc. C. Org., 1967,1504 .
(33) Clarke E. A. and Grundon M. F., Synthesis of (±)-Lunacridine and (±)lunacrine. Chem. Ind., 1962,556-557
(34) Kuwayama Y., Studies on the use of γ-Butyrolactone VI. A new synthesis of dihydrodictamnine. Chem. Pharm. Bull., 1961, 9,719-722 .
(35) http://www.doh.gov.tw/cht2006/index_populace.aspx(衛生署網站)
衛生署:首頁>衛生署新聞>95 年>95 年06 月份新聞---標題：
國人主要死因統計。
(36)張天鈞；台大內科學講義，橘井文化事業股份有限公司，台北市，
2001，第三版，192頁。
(37) Hoffman B. F., and Cranefield P. F., The Physiological Basis of
Cardiac Arrhythmias. Am. J. Med.,1964,37,670-684
(38) Franciosa J. A., Wilen M. Z., Cohn J. N. S., Survival in man with severe chronic left ventricular failure due to either coronary artery disease or idiopathic dilated cardiomyopathy. Am. J. Cardiol., 1983, 51, 831-836 .
(39) Wilson J. R., Schwartz J. S., Sutton M. S., Prognosis in severe heart failure, relation to hemodynamic measurement and ventricular ectopicactivity. J. Am. Cell. Cardiol., 1983,2, 403 .
(40) Meinertz T., Hoffinann T., Kasper W., Significance of ventricular arrhy- thmias in idiopathic dilated cardiomyopathy. Am. J. Cardiol., 1984 , 53, 902-907
(41) Chakko C. S., Gheorghiade M., Ventricular arrhythmia in severe heart failure incidence significance and effectiveness of antiarrhythmic therapy. Am. J. Cardiol., 1985, 52, 14 .
(42) Lathrop D. A., Varro A., Schwartz A., Rate-dependent electrophysiological effects of OPC-8212, Comparison to Sotalol. Eur. J. Phamacol., 1989, 164, 487-496 .
(43) Lathrop D. A., Nanasi P. P., Schwartz A., Varro A., Ionic basis for OPC-8212 induced increase in action potential duration in isolated rabbit guinea-pig and human ventricular myocytes. Eur. J. Pharmacol., 1993, 240, 127-137 .
(44) Su M. J., Chang Y. M., Chi J. F., Lee S. S., Thaliporphine, a positive inotropic agent with a negative chrorotropic action. Eur. J. Pharmacol., 1994, 254, 141-150 .
(45) Beregi J. P., Escande P., Coudray N., Mery P., Mestre M., Chamta D., Lecarpentier Y., Positive inotropic eltbcts of RP- 62719, a new pure class 3 antiarrhythmic agent, on guinea-pig myocardium. Eur .J. Pharmacol., Exp. Ther., 1992, 263, 1369 .
(46) Camm A. J., Yap Y.G., What should we expect from the next genera- tion of antiarrhythmic drugs? J. Cardiovasc Eletrophysiol., 1999, 10, 307-317
(47) Danish Investigator of Arrhythmia and Mortality on Dofetilide. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infraction: rational design, and patient characteristics of the DIAMOND studies. Clin. Cardiol., 1997, 20, 704-710
(48) Doval H. C., Nul D. R., Grancelli H. O., Perrone S. V., Bortman G.R., Curiel R., Randomized trial of low-dose amiodarone in severe congestive heart failure. Lancet ,1994, 344, 493-498
(49) Garg R., Packer M., Pitt B., Yusuf S., Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medi- cine. J. Am. Coll. Cardiol., 1993, 22(Suppl A): 3A-5A .
(50) Gibson J. K., Kersten J. A., In vivo assessment of class III antiarrh- tyhmic agents and their antiarrhythmic activity. Drug Dev. Res.,1990, 19, 173-185.
(51) Hilleman D., Miller M. A., Paker R., Doering P., Pieper J. A., Opti- mal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy, 1998, 18, 138S-145S .
(52) Hondeghem L. M., Development of class II antiarrhythmic agents . J. Cardiovasc Pharmacol.,1992, 20(Suppl. 2), S17-22 .
(53) Jafari-Fesharaski M., Scheinman M. M.,Adverse effects of amioda- rone. Pacing Clin. Electrophysiol. ,1998, 21, 108-120 .
(54) Julian D. G., Camm A. J., Frangin G., Janse M. J., Munoz A., Schwartz P. J., Simon P., Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infraction: EMIAT-European Myocardial Infract Amio- darone Trial, Investigators, Lancet. , 1997, 349, 667-674 .
(55) Julian D. G., Jackson F. S., Szekely P., Prescott R. J., A controlled trial of sotalol for 1 year after myocardial infraction: EMIAT- European Myocardial Infraction, Circulation, 1993, 67, 667-674 .
(56) Massie B. M., Fisher S. G., Radford M., Deewania P. C., Singh B. N., Fletcher R. D., Singh S. N., Effect of amiodarone on clinic status and left ventricular function in patients with congestive heart failure. Circulation, 1996, 3, 2112-2134.
(57) Mätyus P., Varro A., Papp J. G., Wamhoff H., Varga I., Virag L.,Anti- arrhythmic agents: current status and perspectives. Med. Res. Rev. , 1997, 17, 427-451.
(58) Mätyus P., Rettegi T., Varro A., Papp J. G. Y.,New antiarrhythmic agents : a conceptually novel approach. Med. Res. Rev. , 2000, 20, 294-303
(59) O’Connor C. M., Gattis W. A., Swedberg K., Current and novel phar-
macological approaches in advanced heart failure. Am. Heart J., 1998, 135, S249- S263 .
(60) Schlepper M., Cardiodepressive effects of antiarrhythmic drugs. Eur. Heart J., 1999, 10, E73-E80 .
(61) Sim I., McDonald K. M., Lavori P. W., Norbutas C. M., Hlatky M. A, Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation, 1997, 96, 2823-2829 .
(62) Waldo A. L., Camm A. J., de Ruyter H., Friedman P. L., MacNiel D. J., Pauls J. F., Pitt B., Pratt C. M., Schwartz P. J., Veltri E. P., Effect of d-sotalol on mortality in patients with left ventricular dysfuction after recent and remote myocardial infraction. The SWORD Inves- tigators, Suvival With Oral d-Sotalol. Lancet, 1996, 348, 7-12 .
(63) Walker M. J., Curtis M. J., Hearse D. J. et al.,The Lambeth Conven- tions : guidelines for the study of arrhythmias in ischemia infraction, and reperfusion. Cardiovasc Res., 1998, 22, 447-455 .
(64) Szeto H.H., Mitochondria-Targeted Peptide Antioxidants: Novel Neuroprotective Agents. AAPS J., 2006, Aug 18;8(3), E521-31.
(65) Zorov D.B., Juhaszova M., Sollott S.J., Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta., 2006, May-Jun;1757(5-6), 509-17.
(66) Christophe M., Nicolas S., Mitochondria: a target for neuro-
protective interventions in cerebral ischemia-reperfusion. Curr Pharm Des., 2006, 12(6), 739-57.
(67) Roy J., Soberman, The expanding network of redox signaling: new observations,complexities,and perspectives., J. Clin. Invest., 2003, 111, 571–574.
(68) Zmijewski J.W., Landar A., Watanabe N., Dickinson D.A., Noguchi N., Darley-Usmar V.M.,Cell signalling by oxidized lipids and the role of reactive oxygen species in the endothelium. Biochem Soc Trans., 2005, Dec;33(Pt 6), 1385-9
(69) Cooper C.E., Patel R.P., Brookes P.S., Darley-Usmar V.M., Nano-
transducers in cellular redox signaling: modification of thiols by reactive oxygen and nitrogen species., Trends Biochem Sci.,
2002, Oct;27(10), 489-92.
(70) Earl R. Stadtman ,Role of oxidant species in aging., Current Medicinal Chemisry,2004, 11, 1105-1112
(71) Patel R.P., Moellering D., Murphy-Ullrich J., Jo H., Beckman J.S., Darley-Usmar V.M., Cell signaling by reactive nitrogen and oxygen species in atherosclerosis., Free Radical Biol Med., 2000, 28,1780- 1794.
(72) Shiva S., Moellering D., Ramachandran A., Levonen A.L., Landar A., Venkatraman A., Ceaser E., Ulasova E., Crawford J.H., Brookes P.S., Patel R.P., Darley-Usmar V.M., Redox signalling:from nitric oxide to oxidized lipids., Biochem Soc Symp., 2004, (71), 107-20.
(73) Forman H.J., Fukuto J.M., Torres M., Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can
act as second messengers., Am J Physiol Cell Physiol., 2004, Aug; 287(2), C246-56.
(74) Hebestreit H., Dibbert B., Balatti I., Braun D., Schapowal A., Blaser K., Simon H.U., Disruption of fas receptor signaling by nitric oxide in eosinophils., J Exp Med., 1998, Feb 2;187(3), 415-25.
(75) Um, H.D., Orenstein, J.M., Wahl, S.M., Fas mediates apoptosis in
human monocytes by a reactive oxygen intermediate dependent
pathway. J.Immunol., 1996, 156, 3469-3477.
(76) Chiba T., Takahashi S., Sato N., Ishii S., Kikuchi K., Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells., Eur. J. Immunol., 1996, 26, 1164-1169.
(77) Roth J.A., Kaeberle M.L., Effects of in vivo dexamethasone administration on in vitro bovine polymorphonuclear leukocyte function. Infect Immun., 1981, Aug;33(2), 434-41.
(78) Cai T.Q., Weston P.G., Lund L.A., Brodie B., McKenna D.J., Wagner W.C., Association between neutrophil functions and periparturient disorders in cows. ,Am J Vet Res., 1994, Jul; 55(7), 934-43.
(79) Tkalcevic J., Novelli M., Phylactides M., Iredale J.P., Segal A.W., Roes J. Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G., Immunity, 2000, Feb;12(2), 201-10.
(80) Nagahata H., Bovine leukocyte adhesion deficiency (BLAD): a review. J Vet Med Sci., 2004, Dec;66(12), 1475-82.
(81) Rinaldi M., Moroni P., Paape M.J., Bannerman D.D., Evaluation of assays for the measurement of bovine neutrophil reactive oxygen species.,Vet Immunol Immunopathol., 2007, Jan 15;115(1-2),107-25.
(82) Touyz R.M., Reactive oxygen species and angiotensin II signaling in vascular cells --implications in cardiovascular disease., Braz J Med Biol Res., 2004, Aug;37(8), 1263-73.
(83) Taniyama Y., Griendling K.K., Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension, 2003, Dec;42(6), 1075-81.
(84) Upadhyay D., Kamp D.W., Asbestos-induced pulmonary toxicity: role of DNA damage and apoptosis. Exp Biol Med (Maywood)., 2003, Jun;228(6), 650-9.
(85) Gilgun-Sherki Y., Rosenbaum Z., Melamed E., Offen D.,Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev., 2002, Jun;54(2), 271-84.
(86) Tsutsui H., Mitochondrial oxidative stress and heart failure. Intern Med., 2006, 45(13), 809-13.
(87) Wright E., Jr, Scism-Bacon J.L., Glass L.C., Oxidative stress in type 2 diabetes:the role of fasting and postprandial glycaemia. Int. J. Clin. Pract., 2006, Mar;60(3), 308-14.
(88) Wold L.E., Ceylan-Isik A.F., Ren J., Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta. Pharmacol. Sin., 2005, Aug;26(8), 908-17.
(89) Andreyev A.Y., Kushnareva Y.E., Starkov A.A., Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc)., 2005, Feb;70(2), 200-14.
(90)沈珝琲、方福德：真核基因表達調控，九州圖書文物有限公司，1999，第1 版，138~141。
(91) Stefan Offermamnns, Walter Rosenthal, Encyclopedic reference of molecular pharmacology., Springer-Verlag Berlin Heidelberg, 2004, 140~141.
(92) Saraste A., Pulkki K., Morphologic and biochemical hallmarks of apoptosis.,Cardiovasc Res.,2000, Feb;45(3), 528-37. Review.
(93) 李權益：分子生物學 合記圖書出版 第1 版1998，326~332。
(94) 賴慕賢、張乃忠：生化學與分子生物學-原理與實用，合記圖書出版社，2006，初版，247~255。
(95) Scott H., Kaufmann, Apoptosis Pharmacological implications and
therapeutic opportunities.,Academic Press, Vol. 41, 1~5.
(96) Lowe S.W., Lin A.W., Apoptosis in cancer. Carcinogenesis, 2000, Mar; 21(3), 485-95.
(97) Albert B., Johnson A., Lewis J., Raff M., Roberts K.,Walter P., Mo-
lecular biology of the cell.The cell cycle and programmed cell death.
Garland Science. Taylor &Francis Group, 2001, 17,983~ 1125.
(98) Yigong Shi, A structural view of mitochondria-mediated apoptosis. Experimental Cell Research,2000, Volume 256, Issue 1, 10, 12-18.
(99) Andreas Gewies, Introduction to apoptosis. ApoReview, 2003, 1~26.
(100) Guoqing Chen, David V.Goeddel., TNF-R1 Signaling: A Beautiful Pathway. Science, 2002, 31 May: Vol. 296. no. 5573, 1634 -1635.
(101) Wajant H., The Fas signaling pathway: more than a paradigm. Science, 2002, May 31;296(5573), 1635-6.
(102)Murphy K.M., Ranganathan V., Farnsworth M.L., Kavallaris M., Lock R.B., Bcl-2 inhibits Bax translocation from cytosol to mito- chondria during drug-induced apoptosis of human tumor cells.
Cell Death Differ., 2000, Jan;7(1), 102-11.
(103) Santos A., Susin, Eric Daugasa, Luigi Ravagnan etc., Two Distinct Pathways Leading to Nuclear Apoptosis. The Journal of Experime- ntal Medicine., 2000, 192(4), 571-580.
(104) Desagher S., Martinou J.C., Mitochondria as the central control point of apoptosis. Trends Cell Biol., 2000, Sep;10(9):369-77.
(105) Herr I., Debatin K.M., Cellular stress response and apoptosis in cancer therapy. Blood., 2001,Nov 1;98(9), 2603-14.
(106) Broker L.E., Kruyt F.A., Giaccone G.., Cell Death Independent of Caspases: A review Clin Cancer Res., 2005, May 1;11(9), 3155-62.
(107) Fan T.J., Han L.H., Cong R.S., Liang J., Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai), 2005, Nov; 37(11), 719-27.
(108) Smaili S.S., Hsu Y.T., Carvalho A.C., Rosenstock T.R., Sharpe J.C., Youle RJ. Mitochondria,calcium and pro-apoptotic proteins as mediators in cell death signaling. Braz J Med Biol Res.,2003, Feb;36(2), 183-90.
(109) Duchen M.R., Mitochondria and calcium: from cell signalling to cell death. J Physiol., 2000,Nov 15;529 Pt 1:57-68.
(110) Wang, X., The expanding role of mitochondria in apoptosis. Genes Dev., 2001, 15, 2922-2933.
(111) Gerald Karp 原著，廖珍琦、呂長益、周中興編譯：Cell and molecular biology, Concepts and experiments 3e,(細胞與分子生物學，觀念與實驗)，合記圖書出版社，2004，初版：662~666。
(112) Stefan J., Riedl and Yigong Shi , Molecular mechanisms of caspase regulation during apoptosis, Nature reviews, molecular cell biology, 2004, Vol 5, Nov, 897~907.
(113) Smaili S.S., Hsu Y.T., Youle R.J., Russell J.T., Mitochondria in Ca2+ signaling and apoptosis. J Bioenerg Biomembr., 2000, Feb; 32(1):35-46.
(114) Duchen M.R., Mitochondria and calcium: from cell signalling to cell death. J Physiol., 2000, Nov 15;529 Pt 1:57-68.
(115) Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., Sheu S.S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004, Oct;287(4):C817-33.
(116) http://www.weizmann.ac.il/home/ligivol/apoptosis_project
/apoptosis.jpg(圖片來源)
(117) Berridge M.J., The endoplasmic reticulum: a multifunctional
signaling organelle. Cell Calcium.2002, Nov-Dec;32(5-6):235-49
(118) Thomenius M.J., Distelhorst C.W., Bcl-2 on the endoplasmic
reticulum: protecting the mitochondria from a distance. J Cell Sci.,
2003, Nov 15;116(Pt 22), 4493-9.
(119) Verkhratsky A., Toescu E.C., Endoplasmic reticulum Ca2+ homeo-
stasis and neuronal death. J Cell Mol Med., 2003, Dec;7(4), 351-61.
(120) Fan T.J., Han L.H., Cong R.S., Liang J., Caspase family proteases
and apoptosis. Acta BiochimBiophys Sin (Shanghai)., 2005,Nov;
37(11), 719-27.
(121) Kass G.E., Orrenius S., Calcium signaling and cytotoxicity.
Environ Health Perspect., 1999, Feb; 107 Suppl 1, 25-35.
(122) Kadenbach B., Arnold S., Lee I., Huttemann M., The possible role
of cytochrome c oxidase in stress-induced apoptosis and degenerative
diseases. Biochim Biophys Acta., 2004, Apr 12;1655(1-3), 400-8.
(123) Nicholls D.G., Mitochondrial membrane potential and aging. Aging
Cell, 2004, Feb;3(1), 35-40.
(124) Samraj A.K., Sohn D., Schulze-Osthoff K., Schmitz I., Loss of Caspase-9 Reveals Its Essential Role for Caspase-2 Activation and Mitochondrial Membrane Depolarization.Mol Biol Cell., 2007,
18(1), 84-93 .
(125) Machiavelli L.I., Poliandri A.H., Quinteros F.A., Cabilla J.P.,
Duvilanski B.H., Reactive oxygen species are key mediators of the
nitric oxide apoptotic pathway in anterior pituitary cells, Nitric
Oxide., 2007, 16(2), 237-246.
(126) Smaili S.S., Russell J.T., Permeability transition pore regulates both
mitochondrial membrane potential and agonist-evoked Ca2+ signals
in oligodendrocyte progenitors. Cell Calcium., 1999, Oct;26(3-4),
121-30.
(127) Skarka L., Ostadal B., Mitochondrial membrane potential in cardiac
myocytes. Physiol Res., 2002, 51(5):425-34.
(128) Iijima T., Mitochondrial membrane potential and ischemic neuronal
death. Neurosci Res., 2006,Jul;55(3):234-43.
(129) Salvioli S., Ardizzoni A., Franceschi C., Cossarizza A., JC-1, but
not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to
assess delta psi changes in intact cells: implications for studies on
mitochondrial functionality during apoptosis. FEBS Lett., 1997, Jul
7;411(1), 77-82.
(130) http://www.sgul.ac.uk/depts/immunology/~dash/apoptosis/
mito.html(圖片來源)
(131)Zhou B.B., Elledge S.J., The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
(132) O''Connell M.J., Cimprich K.A., G2 damage checkpoints: what is
the turn-on? J Cell Sci., 2005 Jan 1;118(Pt 1):1-6.
(133) Ionov Y., Yamamoto H., Krajewski S., Reed J.C., Perucho M:
Mutational ?ninactivation of the proapoptotic gene BAX confers
selective advantage during tumor. Proc. Natl. Acad. Sci., 2000,
Sep 26;97(20):10872-7.
(134) Brown J.M., Wouters B.G., Apoptosis, p53, and tumor cell
sensitivity to anticancer agents.Cancer Res., 1999, 59:1391-1399.
(135) Tannock I.F., Lee C., Evidence against apoptosis as a major
mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer, 2001, 84:100-105.
(136) Kuo S. C., Lin T. P., Lin L. D., Hsu H. Y. and Wu C. H., Synthetic Investigation of Glycarpine.J. Nat Prod, 1984, 47, 47-51 .
(137) Kuo S. C., Lin T. P., Chang S. S., Wu C. H., Shieh B. J. and Chou T. C., Synthetic Investigation of Taifine, J .Nat. Prod., 1986, 49, 48-55.
(138) Lin T. P. and Shieh B. J., Study on the constituents of Furoquinoline alkaloids from Pai-Shen pi (Dictamnus dasycarpus Turz) in Ruta- ceae , Chemistry (Chinese), 1986, 44,96-100 .
(139) Lin T. P., Shieh B. J. and Kuo S. C., Study on the constituents of Furoquinolone alkaloids in Rutaceae, Synthetic Investigation of Isomaculosidine, J .Nat. Prod. ,1986, 44, 631 .
(140) Lin T. P., Shieh B. J. and Kuo S. C., Study on the constituents of Furoquinolone alkaloids in Rutaceae, Synthetic Investigation of Isodictamnine. Chemistry (Chinese),1987,45, 45-49 .
(141) Shieh B. J. and Lin T. P., Study on the constituents of Furoquinolone alkaloids in Rutaceae,Synthetic Investigation of Isotaifine Chemistry,(Chinese), 1990, 48,309-316 .
(142) Shieh B. J. and Lin T. P., Study on the constituents of Furoquinlone alkaloids in Rutaceae, Synthetic Investigation of acrophylline. Chemistry, (Chinese), 1990, 48, 259-264 .
(143) Kuo S. C.,Huang S. C.,Cheng H. E.,Lin T. P.,Wu C. H.,Ishii K. and Nakamura H. K., Synthesis and antiinflammatory and antiallergic activity of N-Alkyl-2,3,4,9-tetrahydrofuroquinolindione and Related compounds. J. Heterocyclic Chem. 1991, 28, 955-963 .
(144) Wang J. P., Tsao L. T., Raung S. L., Hsu M. F., and Kuo S. C.,Inhibition by HAJ11 of respiratory burst in neutrophils and the involvement of protein tyrosine phosphorylation and phospholipase D activation, Br. J. Pharmacol., 1997, 120, 79-83 .
(145) Chang C. P., Lin T. P., Wang J. P, and Kuo S. C., Synthesis and biological activity of N-substituted benzyl-6(or7)-ethyl-2,3,4,9-tetra- hydrofuro[2,3-b]quinolin-3,4-diones. Chin. Pharm.J.,2001,53(5),239 -256 .
(146) Lin T. P., Chang C. P., Tsung Z. T. and Wang J. P., Synthesis and biological activity of N-substituted benzyl-6(or7)-chloro-2,3,4,9- tetrahydrofuro[2,3-b]quinolin-3,4-diones. Chin. Pharm. J., 2002, 54, 115-126.
(147) Su M. J., Chang G. J., Wu M. H. and Kuo S. C,Electrophysiological basis for the antiarrhythmic action and positive inotropy of HA-7, a furoquinoline alkaloid derivative, in rat heart. British J. of Pharmacology, 1997, 122,1285-1298 .
(148) Cheng Y. C., Synthesis and Biological Activity of N-substituted
benzyl-6(7 or 8)-bromo-2,3,4,9-tetrahydrofuro[2,3-b]quinolin-3,4-
dione , 2001, 中國醫藥大學藥化所碩士論文
(149) Su I.F., Synthesis and Biological Activity of Ethyl 2-[N-substituted benzyl-4¢(or 3¢)-bromo]anilino-4-oxo-4,5-dihydrofuran-3- carboxylate, 2006, 中國醫藥大學藥化所碩士論文
(150) Huang A.C.，Synthesis and Biological Activity of Certain Ethyl 2-[N-various benzyl]Substituted anilino-4-oxo-4,5-dihydrofuran-3- carboxylate,2007, 中國醫藥大學藥化所博士論文
(151) Huang S.M., Synthesis and Biological Activity of Ethyl 2-[N- substituted benzyl-(2''-fluoro(or methoxy))]anilino-4-oxo-4,5- dihydrofuran-3-carboxylate ,2004, 中國醫藥大學藥化所碩士論文
(152) Lan T. S., Synthesis and Biological Activity of Ethyl 2-（N-substituted
benzyl）pyridylamino-4-oxo-4,5-dihydrofuran-3-carboxylate and Related compounds. ,2005, 中國醫藥大學藥化所碩士論文
|